share_log

US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could Be Next

US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could Be Next

美国卫生与公共服务部公布成本节约情况,包括诺华开发的癌症药物,奥捷匹或许会是下一个
Benzinga ·  14:51

Monday, the U.S. Department of Health and Human Services (HHS) announced that Medicare enrollees will benefit from reduced prices on 54 drugs through Medicare Part B, effective from October 1, 2024, to December 31, 2024.

周一,美国卫生与公共服务部(HHS)宣布,从2024年10月1日至2024年12月31日期间,通过Medicare b部分降低了54种药品的价格,医疗保险参与者将受益。

The program aims to counter drug price hikes that exceed inflation, providing financial relief for over 822,000 Medicare beneficiaries who rely on these medications to treat conditions like cancer, osteoporosis, and pneumonia.

该计划旨在对抗超过通货膨胀的药品价格上涨,为超过82.2万名依赖这些药物治疗癌症、骨质疏松症和肺炎等疾病的医疗保险受益人提供经济救济。

Also Read: Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk's Wegovy

另请阅读:在诺和诺德的Wegovy上,医生努力为心脏病患者提供医疗保险

HHS Secretary Xavier Becerra emphasized that the Biden administration's prescription drug policies are making a tangible impact on seniors and people with disabilities by reducing out-of-pocket costs.

国土安全部部长泽维尔·贝塞拉强调,拜登政府的处方药政策通过降低自付成本,正在对老年人和残疾人产生切实影响。

According to Chiquita Brooks-LaSure, CMS Administrator, some Medicare beneficiaries could see daily savings ranging from $1 to as much as $3,854 on drugs included in the rebate program.

根据CMS管理员奇基塔·布鲁克斯-拉苏尔的说法,一些医疗保险受益人购买回扣计划中包含的药品每天可以节省1美元到多达3,854美元。

For example, a cancer patient using Novartis' AGs (NYSE:NVS) Kymriah could save up to $3,000.

例如,使用诺华AGS(纽约证券交易所代码:NVS)Kymriah的癌症患者最多可以节省3,000美元。

Brooks-LaSure also noted that the law disincentivizes drug companies from raising prices faster than inflation, which helps protect Medicare beneficiaries from sharp price increases.

布鲁克斯-拉苏尔还指出,该法律抑制了制药公司以比通货膨胀更快的速度提高价格,这有助于保护医疗保险受益人免受价格急剧上涨的影响。

The Inflation Reduction Act's initiatives extend beyond 2024. In August, the administration reached new agreements to reduce prices for ten additional high-cost drugs.

《减少通货膨胀法》的举措将延续到2024年以后。8月,政府达成了新的协议,以降低另外十种高成本药品的价格。

Once these prices take effect in 2026, Medicare is projected to save an estimated $6 billion, while beneficiaries could see a reduction of $1.5 billion in out-of-pocket expenses.

一旦这些价格在2026年生效,医疗保险预计将节省约60亿美元,而受益人的自付支出可能会减少15亿美元。

Starting in 2025, Medicare Part D enrollees will further benefit from a $2,000 annual cap on prescription drug costs, down from the current cap of $3,500 for those with high expenses.

从2025年开始,Medicare D部分参与者将进一步受益于每年2,000美元的处方药费用上限,低于目前高支出者的3500美元上限。

According to some analysts, Novo Nordisk A/S' (NYSE:NVO) blockbuster diabetes drug Ozempic might be included, along with several other well-known medications, in the next round of negotiations, which is set for 2027.

一些分析师认为,诺和诺德A/S(纽约证券交易所代码:NVO)的重磅糖尿病药物Ozempic以及其他几种知名药物可能会被纳入定于2027年的下一轮谈判。

  • TPG, GIC Agree To Buy Techem For $7.5B: Look To Expand 'Across Europe And Beyond'
  • TPG、GIC同意以75亿美元收购Techem:希望在 “欧洲及其他地区” 扩张

Photo via Shutterstock

照片来自 Shutterstock

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发